Released: 01/20/21

If you are positive for COVID-19 and meet the criteria listed below, you may be a candidate for monoclonal antibody medication.  Monoclonal antibody medication may help decrease the risk of severe illness and complications due to COVID-19, and is most effective if received early in the onset of the infection. Choosing to get monoclonal antibody treatment should be based on risk factors and not on current symptoms or waiting to see what symptoms develop.

Upon receiving positive COVID-19 test results, call Winneshiek Medical Center at 563-382-2911 and ask for an appointment in the Respiratory Illness Clinic to discuss your options with a health care provider. 

Please bring documentation of your COVID-19 test result with you to the appointment.  Patients treated with this medication should continue to self-isolate and use infection control measures, according to CDC guidelines.

Monoclonal Antibody Medication Criteria

  1. COVID-19 positive AND
  2. Within 10 days of symptom onset AND
  3. Mild or Moderate COVID-19 AND
  4. Older than 12 years of age AND
  5. Weigh > 40 kg (88 lbs) AND
  6. At high risk* for progressing to severe COVID-19 and/or hospitalization

*High risk is defined as patients who meet at least one of the following criteria:

  • Have a body mass index (BMI) ≥35
  • Have chronic kidney disease
  • Have diabetes
  • Have immunosuppressive disease
  • Are currently receiving immunosuppressive treatment
  • Are ≥65 years of age
  • Are ≥55 years of age AND have
    • cardiovascular disease, OR
    • hypertension, OR
    • chronic obstructive pulmonary disease/other chronic respiratory disease.
  • Are 12 – 17 years of age AND
    • Have BMI ≥85th percentile for their age and gender based on CDC growth charts,, OR
    • sickle cell disease, OR
    • congenital or acquired heart disease, OR
    • neurodevelopmental disorders, for example, cerebral palsy, OR
    • a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19), OR

asthma, reactive airway or other chronic respiratory disease that requires daily medication for control

Return to Press Room

Source link